Royal Bank Of Canada Upgrades Revvity (NYSE:RVTY) to Hold

Key Points

• Royal Bank of Canada upgraded Revvity to “Hold,” joining a broader consensus that includes 13 Hold ratings and three Buy ratings. Analysts’ average price target is $110.58.
• Revvity reported quarterly EPS of $1.41, beating estimates of $1.21, while revenue of $729.69 million also exceeded forecasts; however, revenue declined 1.3% year over year.
• Shares opened at $126.59, near their 52-week high of $130.07, with 86.65% of the stock held by institutional investors and hedge funds.

Revvity (NYSE:RVTY - Get Free Report) was upgraded by Royal Bank Of Canada to a "hold" rating in a research report issued on Tuesday, Zacks reports.

A number of other equities research analysts have also recently weighed in on RVTY. JPMorgan Chase & Co. cut their price objective on shares of Revvity from $96.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 6th. Robert W. Baird set a $117.00 price target on shares of Revvity in a research note on Wednesday, May 6th. Zacks Research upgraded shares of Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Stifel Nicolaus lowered their price objective on shares of Revvity from $110.00 to $100.00 and set a "hold" rating on the stock in a research note on Wednesday, May 6th. Finally, TD Cowen reissued a "buy" rating on shares of Revvity in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $110.58.

Revvity Stock Down 1.6%

RVTY stock opened at $126.59 on Tuesday. The stock has a market cap of $14.13 billion, a PE ratio of 60.28, a price-to-earnings-growth ratio of 2.34 and a beta of 1.09. The firm's 50-day simple moving average is $115.22 and its 200 day simple moving average is $101.55. Revvity has a fifty-two week low of $81.22 and a fifty-two week high of $130.07. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.21 by $0.20. The firm had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. Revvity's revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Revvity will post 5.36 EPS for the current year.

Institutional Investors Weigh In On Revvity

Institutional investors and hedge funds have recently bought and sold shares of the business. Ascentis Independent Advisors acquired a new position in shares of Revvity in the 1st quarter worth approximately $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity during the second quarter valued at approximately $32,000. MUFG Securities EMEA plc acquired a new position in Revvity in the second quarter worth approximately $34,000. SJS Investment Consulting Inc. grew its position in Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company's stock worth $47,000 after buying an additional 521 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Revvity in the second quarter valued at $49,000. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source